Title: Healthcare costs incurred by patients with Multiple Myeloma following Triple Class Exposure (TCE) in the US

Authors: Sundar Jagannath,¹ MD; Nedra Joseph,² PhD; Jinghua He,³ PhD; Concetta Crivera,² PharmD MPH; Alex Z Fu,³,⁴ PhD; Ashraf Garret,⁵ PharmD, RPh; Nina Shah,⁶ MD

Affiliations
¹ Icahn School of Medicine at Mount Sinai, New York, NY USA
² Janssen Scientific Affairs, LLC, Horsham, PA USA
³ Janssen Scientific Affairs, LLC, Titusville, NJ USA
⁴ Georgetown University Medical Center, Washington, DC USA
⁵ Legend Biotech Inc. Piscataway, NJ USA
⁶ University of California San Francisco, San Francisco, CA USA

Corresponding author
Nedra Joseph
Real World Value & Evidence (Oncology)
Janssen Scientific Affairs, LLC
Horsham, PA USA
PJJoseph3@ITS.JNJ.com
Supplementary Table 1. List of NCCN Guideline Recommended MM Treatments [6]

| Drug class                      | Drug name                                           |
|---------------------------------|-----------------------------------------------------|
| Immunomodulatory drug           | Thalidomide (Synovir, Thalomid) Lenalidomide (Revlimid) Pomalidomide (Pomalyst) |
| Proteasome inhibitor            | Bortezomib (Velcade) Carfilzomib (Kyprolis) Ixazomib (Ninlaro) |
| Targeted monoclonal antibody    | Daratumumab (Darzalex) Isatuximab (Sarclisa) Elotuzumab (Empliciti) |
| Histone deacetylase inhibitor   | Panobinostat (Farydak)                              |
| Nuclear export inhibitor        | Selinexor (Xpovio)                                  |
| Chemotherapy                    | Cyclophosphamide (Cytoxan) Melphalan (Alkeran) Doxorubicin (Adriamycin, Doxil) Etoposide (Toposar, VePesid) Cisplatin (Platinol) Bendamustine (Treanda, Belrapso, Bendeka) Cytarabine/Pf Methotrexate sodium/Pf, methotrexate |
| Corticosteroid                  | Prednisone Dexamethasone                            |
| Other                           | Belantamab mafodotin (Blenrep) Vincristine           |

MM: Multiple myeloma; NCCN: National Comprehensive Cancer Network